Chest
ORIGINAL RESEARCHASTHMAThe Effect of Montelukast and Low-Dose Theophylline on Cardiovascular Disease Risk Factors in Asthmatics
Section snippets
Study Subjects
The Effectiveness of Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) clinical trial was a recently completed, randomized, double-masked, placebo-controlled, parallel-designed trial of the effectiveness of montelukast and low-dose theophylline in the treatment of patients with poor asthma control.11 Briefly, 489 patients were recruited from 19 centers in the American Lung Association Asthma Clinical Research Centers. Participants were between the ages of 15 and 79
Results
Baseline characteristics of the 489 participants in the LODO clinical trial are shown in Table 1. The three treatment groups were well matched with respect to age, gender, ethnicity, obesity, and parameters related to asthma. In addition, there were no significant differences in the percentage of patients receiving various asthma medications among the three treatment groups (Table 1).
Overall, we observed a nonsignificant trend toward lower CRP and IL-6 levels in the montelukast and theophylline
Discussion
In the present study, we have provided evidence that asthma patients receiving the 5-LO pathway modifier montelukast or low-dose theophylline have lower blood risk factors associated with CVD compared to patients receiving placebo. Although these observations are from retrospective analyses of an already completed trial, they suggest that montelukast and low-dose theophylline could potentially reduce inflammatory CVD risk in asthmatics currently receiving these medications. This may be
ACKNOWLEDGMENT
We thank the patients for participating in the LODO clinical trial.
References (27)
- et al.
Lung function and ischemic stroke incidence: the Atherosclerosis Risk in Communities study
Chest
(2006) - et al.
C-reactive protein, inflammation, and coronary risk
Cardiol Clin
(2003) - et al.
Identifying “well-controlled” and “not well-controlled” asthma using the Asthma Control Questionnaire
Respir Med
(2006) - et al.
Drugs causing dyslipoproteinemia
Endocrinol Metab Clin North Am
(1998) Asthma, body mass index, and C-reactive protein among US adults
J Asthma
(2003)- et al.
Chlamydia pneumoniaeinfection and inflammation in adults with asthma
Respiration
(2004) - et al.
High sensitivity C-reactive protein in asthma
Eur Respir J
(2006) - et al.
Are patients with asthma at increased risk of coronary heart disease?
Int J Epidemiol
(2004) - et al.
Adult-onset asthma is associated with increased carotid atherosclerosis among women in the Atherosclerosis Risk in Communities (ARIC) study
Atherosclerosis
(2006) - et al.
5-Lipoxygenase and atherosclerosis
Curr Opin Lipidol
(2003)
Leukotriene receptors in atherosclerosis
Ann Med
Inflammatory markers and the risk of coronary heart disease in men and women
N Engl J Med
Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma
Am J Respir Crit Care Med
Cited by (52)
Evaluating the effect of montelukast tablets on respiratory complications in patients following blunt chest wall trauma: A double-blind, randomized clinical trial
2023, Chinese Journal of Traumatology - English EditionCitation Excerpt :In the present study, the volume of damaged lungs measured by CT scan and C-reactive peptides on day 0 and day 3 did not change significantly in either group. This finding contrasts the results reported by Allayee et al.,15 who showed that montelukast significantly decreased patients' serum C-reactive peptides levels. Rupprecht et al.19 concluded that montelukast decreases ventilator days and the HLOS.
Targeted anti-inflammatory therapy is a new insight for reducing cardiovascular events: A review from physiology to the clinic
2020, Life SciencesCitation Excerpt :Study on the entire Swedish population was performed by Ingelsson et al. and the findings provided a first evidence of the possible role of the antiasthma medication montelukast in secondary CV disease control [208]. In addition, Allayee et al. confirmed that montelukast may lower levels of inflammatory biomarkers and lipid levels correlated with CVD [209]. All the animal studies reported a decrease in the CV and cerebrovascular risk associated with the use of LTRA.
This work was supported by the American Lung Association Clinical Research Centers, the Nemours Research Foundation, and National Institutes of Health grants HL079353 (Dr. Allayee) and HL071394 (Dr. Lima). A portion of this work was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Number C06 (RR10600–01, CA62528–01, RR14514–01) from the National Center for Research Resources.
The authors have no conflicts of interest to disclose.